ScoreWhy is C4 Therapeutics, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -1.90% and Operating profit at -177.92% over the last 5 years
2
Flat results in Sep 25
- NET SALES(HY) At USD 17.69 MM has Grown at -35.35%
- ROCE(HY) Lowest at -59.98%
- RAW MATERIAL COST(Y) Grown by 5.92% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 29.81%, its profits have fallen by -5.1%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is C4 Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
C4 Therapeutics, Inc.
29.81%
-0.41
108.38%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-1.90%
EBIT Growth (5y)
-177.92%
EBIT to Interest (avg)
-76.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.13
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
99.43%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.73
EV to EBIT
-0.68
EV to EBITDA
-0.73
EV to Capital Employed
-2.58
EV to Sales
2.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-70.17%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at -84.47 %
NET SALES(Q)
At USD 11.23 MM has Grown at 31.19%
OPERATING PROFIT(Q)
Highest at USD -21.61 MM
PRE-TAX PROFIT(Q)
Highest at USD -21.43 MM
NET PROFIT(Q)
Highest at USD -21.43 MM
-9What is not working for the Company
NET SALES(HY)
At USD 17.69 MM has Grown at -35.35%
ROCE(HY)
Lowest at -59.98%
RAW MATERIAL COST(Y)
Grown by 5.92% (YoY
Here's what is working for C4 Therapeutics, Inc.
Net Sales
At USD 11.23 MM has Grown at 31.19%
over average net sales of the previous four periods of USD 8.56 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -21.61 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -21.43 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -21.43 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -84.47 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for C4 Therapeutics, Inc.
Raw Material Cost
Grown by 5.92% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
